title: Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin.
abstract: Fibrinogen plays a complex role in hemostasis, thrombosis, and vascular disease. Hyperfibrinogenemia is an independent vascular risk factor and dysfibrinogenemia can provoke thrombosis. Afibrinogenemia is usually responsible for hemorrhagic diathesis, and unexpected ischemic lesions are intriguing. We report the case of an afibrinogenemic patient, who at the age of 30 developed ischemic lesions of the feet related to severe stenosis of the iliac and hypogastric arteries. The biopsy of the iliac artery lesion showed an intense myointimal hyperplasia. We performed standard hemostatic analysis and analyzed the activation markers of platelets and coagulation factors and the kinetics of thrombin generation in the patient and in normal control plasmas treated or not with reptilase. Occlusive arterial lesions were attributed to a disruptive hematoma penetrating the vascular lumen. Thrombin concentration after calcium addition increase markedly in the afibrinogenemic patient and in defibrinated normal plasma, as compared to untreated normal plasma. Thrombin-antithrombin complexes (T-AT) were markedly enhanced while F1+2 prothrombin fragments stayed in the normal range. These results suggested activation of coagulation and in vivo circulating thrombin. Thrombin activates the platelets that secrete growth factors for smooth muscle cells and generate the intimal hyperplasia. Recurrent hemorrhage within the vessel wall might induce injury and local thrombin generation. Thrombin not trapped by the clot is available for platelet activation and smooth muscle cell migration and proliferation. The absence of a protective fibrin cap on the intima might account for intima vulnerability and embolization. Afibrinogenemia appears in this paradoxical situation as a vascular risk factor.
authors.affiliation: Department of Hematology, Hospital Lariboisière, 2 Rue Ambroise Paré, 75475, Paris, France. evelyne.dupuy@lrb.hop-paris.fr
authors.forename: E
authors.initials: E
authors.lastname: Dupuy
authors.forename: C
authors.initials: C
authors.lastname: Soria
authors.forename: P
authors.initials: P
authors.lastname: Molho
authors.forename: J M
authors.initials: JM
authors.lastname: Zini
authors.forename: S
authors.initials: S
authors.lastname: Rosenstingl
authors.forename: C
authors.initials: C
authors.lastname: Laurian
authors.forename: P
authors.initials: P
authors.lastname: Bruneval
authors.forename: G
authors.initials: G
authors.lastname: Tobelem
mesh_terms: D000328:Adult; D000347:Afibrinogenemia / Q000150:complications*; D001157:Arterial Occlusive Diseases / Q000150:complications; D015415:Biomarkers / Q000097:blood; D001780:Blood Coagulation Tests; D004617:Embolism / Q000209:etiology / Q000473:pathology; D006801:Humans; D007083:Iliac Artery / Q000473:pathology; D007511:Ischemia / Q000209:etiology* / Q000473:pathology; D007700:Kinetics; D008297:Male; D015539:Platelet Activation; D013917:Thrombin / Q000378:metabolism; D014034:Toes / Q000098:blood supply / Q000473:pathology*
chemical_list: D015415:Biomarkers; D013917:Thrombin